March 27, 2019 05:17 PM EDT

As AI permeates clinical analytics, Perceptive Advisors bets $40M into a storied player in the field

Amber Tong

When it comes to using artificial intelligence to speed up drug discovery and development, the former may be grabbing the most attention with the crop …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As AI permeates clinical analytics, Perceptive Advisors bets $40M into a storied player in the field

Amber Tong

Sign up to read this article for free.

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Soleno’s rare pediatric disease drug faces PDUFA delay by three months

Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data

As AI per­me­ates clin­i­cal an­a­lyt­ics, Per­cep­tive Ad­vi­sors bets $40M in­to a sto­ried play­er in the field

Amber Tong

Sign up to read this article for free.

more like this

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

As AI permeates clinical analytics, Perceptive Advisors bets $40M into a storied player in the field

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Soleno’s rare pediatric disease drug faces PDUFA delay by three months

Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data